GlassScriptPhysician profile
Tammy Covington
NPI 1831599893
$7,212.46
in general payments reported to CMS, 2019-2025
30 companies · $1,646 in 2025
The $1,646 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,322 · 2022: $923 · 2023: $1,399 · 2024: $1,922 · 2025: $1,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,935 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,934.80 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,705.27 | 2021-2025 | |
| Pfizer INC. | $955.31 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $517.54 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $315.19 | 2021-2025 | Entyvio, Eohilia |
| Aimmune Therapeutics, INC. | $301.76 | 2024-2025 | Zenpep |
| Genzyme Corporation | $284.51 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $279.92 | 2021-2024 | Relistor, Xifaxan, Trulance |
| Janssen Biotech, INC. | $267.58 | 2021-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $196.56 | 2022-2025 | Livdelzi |
| Celgene Corporation | $167.50 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $127.50 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $101.02 | 2022-2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $97.84 | 2021-2023 | Rebyota |
| Vivus LLC | $96.42 | 2021-2024 | Pancreaze |
| Lilly USA, LLC | $91.55 | 2025 | Omvoh |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $90.55 | 2023-2024 | Hadlima |
| Evoke Pharma, INC. | $86.40 | 2021-2023 | Gimoti |
| Merck Sharp & Dohme LLC | $75.27 | 2021-2024 | Dificid |
| Novo Nordisk INC | $74.30 | 2025 | Wegovy |
| Redhill Biopharma INC. | $69.07 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $62.01 | 2021-2023 | |
| Braintree Laboratories, INC. | $50.22 | 2021-2024 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $47.02 | 2024-2025 | Rezdiffra, Resmetirom |
| Axonics, INC. | $30.84 | 2024 | Axonics |
| Exact Sciences Corporation | $27.04 | 2025 | Cologuard Collection Kit |
| Phadia US INC. | $21.96 | 2023 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.40 | 2023 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $19.60 | 2024 | |
| Intercept Pharmaceuticals, INC. | $16.24 | 2023 | Ocaliva |
| Daiichi Sankyo INC. | $15.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Covington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.